SCHEMBL1962099

SCHEMBL1962099

CSc1ccc(C(O)c2cc3cccnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.50
CYP2C19 P33261 1/20 0.42
PTGDR2 Q9Y5Y4 4/20 0.40
MAPT P10636 4/20 0.39
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTR6 P50406 2/20 0.35
ENPP1 P22413 1/20 0.35
KMT2A Q03164 1/20 0.34
PKM P14618 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1960448 0.85 RECQL (0.41) RECQLPTGDR2MAPTTP53SMN1; SMN2
SCHEMBL1962390 0.83 RECQL (0.44) RECQLCYP2C19PTGDR2MAPTTP53
SCHEMBL1959020 0.79 MAPT (0.50) RECQLCYP2C19PTGDR2MAPTALDH1A1
SCHEMBL1960993 0.76 RECQL (0.48) RECQLCYP2C19PTGDR2MAPTALDH1A1
SCHEMBL28987741 0.75 CYP2C19 (0.52) RECQLCYP2C19PTGDR2MAPTSMN1; SMN2
SCHEMBL2924156 0.75 RECQL (0.48) RECQLMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL1963592 0.75 RECQL (0.47) RECQLCYP2C19PTGDR2MAPTALDH1A1
SCHEMBL30337641 0.74 CYP2C19 (0.56) RECQLCYP2C19PTGDR2MAPTALDH1A1
SCHEMBL1772416 0.74 CYP2C19 (0.56) RECQLCYP2C19PTGDR2MAPTALDH1A1
SCHEMBL1959300 0.73 PTGDR2 (0.38) RECQLCYP2C19PTGDR2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 RECQL 3296/4885CYP2C19 792/4885PTGDR2 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.